Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and pharmacodynamics study of saxagliptin in healthy subjects. The trial was sponsored by AstraZeneca and is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED